Analysis of methylation using nucleic acid arrays

Patent metadata

Field	Value
Publication number	US-9828640-B2
Application number	US-201314044737-A
Country	US
Kind code	B2
Filing date	Oct 2, 2013
Priority date	Mar 31, 2006
Publication date	Nov 28, 2017
Grant date	Nov 28, 2017

Abstract

Arrays for genome-wide analysis of methylation are disclosed. In a preferred aspect arrays comprising a plurality of probes complementary to a plurality of identified CpG islands in the human, mouse and rat genome are disclosed. The arrays may be used to detect methylation within CpG islands in samples from human, mouse and rat genomes.

First claim

What is claimed is:

1. A method of analyzing the methylation status of at least one interrogation position in a sample of DNA, the method comprising:
treating the sample to differentiate between methylated and unmethylated sequences;
amplifying the treated sample, such that a fragment comprising the interrogation position is amplified;
contacting the amplified fragment with an array of probes, wherein at least one of the probes in the array hybridizes to the fragment proximal to the interrogation position;
performing single base extension on the probe hybridized to the fragment to generate an extended probe; and
detecting the extended probe, wherein the nucleotide added to the extended probe indicates whether the interrogation position was methylated in the sample of DNA,
wherein the array of probes comprises more than 250,000 different experimental probe features, wherein:
(a) each experimental probe feature comprises a plurality of copies of a nucleic acid probe that is different in sequence from the probes of every other feature of the array;
(b) each experimental probe feature is at a known or determinable location in the array; and
(c) at least 90% of the experimental probe features comprise full length probes that are perfectly complementary to a CpG island, wherein a CpG island is a genomic region that is at least 200 bases and has a GC dinucleotide content of at least 50% over its length.

2. The method of claim 1 , wherein the sample is treated withbisulfite.

3. The method of claim 1 , wherein probes in the array are immobilized onbeads.

4. The method of claim 1 , further comprising:
amplifying untreated sample, such that a fragment comprising the interrogation position is amplified;
contacting the amplified fragment with an array of probes, wherein at least one of the probes in the array hybridizes to the fragment proximal to the interrogation position;
performing single base extension on the probe hybridized to the fragment to generate an extended probe; and
detecting the extended probe, wherein the nucleotide added to the extended probe indicates whether the interrogation position was methylated in the sample of DNA.

5. The method of claim 1 , wherein the full length probes are between 20 and 100 bases in length and are complementary to human, mouse, and/or rat genomic sequences.

6. The method of claim 1 , wherein the full length probes are between 20 and 100 bases in length, and wherein at least 80% of the full length probes comprise at least one CG dinucleotide.

7. The method of claim 6 , wherein at least 50% of the full length probes comprise at least two CG dinucleotides.

8. The method of claim 6 , wherein at least 25% of the full length probes comprise at least three CG dinucleotides.

9. The method of claim 1 , wherein the array of probes further comprising a plurality of control features.

10. The method of claim 9 , wherein the control features comprise one or more control features selected from the group consisting of:
GC matched anti-genomic controls; bacterial genome controls; Arabidopsis genome controls; pseudomonas genome controls; known human gene controls; repeat region controls; 18S rRNA gene controls; 28S rRNA gene controls; and known methylation-regulated gene controls from human, mouse, and/or rat.

11. The method of claim 1 , wherein the array of probes comprises nucleic acid probes selected from SEQ ID NOS: 1 to 222,822.

12. The method of claim 11 , wherein said array of probes comprises at least 1,000,000 different experimental probes.

13. The method of claim 11 , wherein said array of probes comprises at least 500,000 different experimental probes.

14. The method of claim 11 , wherein said array of probes further comprises a plurality of control probes selected from SEQ ID NOS: 668,565 to 693,466.

15. The method of claim 1 , wherein the array of probes comprises nucleic acid probes selected from SEQ ID NOS: 222,823 to 448,233.

16. The method of claim 15 , wherein the array of probes further comprises a plurality of control probes selected from SEQ ID NOS: 693,467 to 715,779.

17. The method of claim 1 , wherein the array of probes comprises nucleic acid probes selected from SEQ ID NOS: 448,234 to 668,564.

18. The method of claim 17 , wherein the array of probes comprises a plurality of control probes selected from SEQ ID NOS: 715,780 to 743,256.

Assignees

• Affymetrix Inc

Inventors

• Cao Yanxiang
• Nautiyal Shivani
• Miyada Charles G
• Davies Christopher
• Mei Gangwu
• Williams Alan J
• Schell Eric B
• Blume John E

Classifications

• C12Q1/6837 Primary

  using probe arrays or probe chips (C12Q1/6874 takes precedence) · CPC title

• C12Q2600/154

  Methylation markers · CPC title

• C12Q2523/125

  Bisulfite(s) · CPC title

• C12Q1/6883 Primary

  for diseases caused by alterations of genetic material · CPC title